Dr Richard Mason joins 4-Antibody as new CEO
This article was originally published in Scrip
4-Antibody (Switzerland) has named Dr Richard Mason chief executive officer and Geschäftsführer. He joins from the venture capital firm Advent Venture Partners, an investor in 4-Antibody, where he has been an executive-in-residence. Previously Dr Mason was senior vice-president of business development at Cambridge Antibody Technology (which was acquired by AstraZeneca).
You may also be interested in...
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.